ORGANOGENESIS HOLDINGS INC. Net Income (Loss) Available to Common Stockholders, Diluted
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$99.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-06
- ORGANOGENESIS HOLDINGS INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$99.34M.
- ORGANOGENESIS HOLDINGS INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$56.16M.
- ORGANOGENESIS HOLDINGS INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was $35.12M, a 497.82% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was $14.53M, a 17.79% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. net income (loss) available to common stockholders, diluted for fiscal 2025 was $20.02M.
- ORGANOGENESIS HOLDINGS INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$937.00K, a 118.95% decline from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was $4.95M, a 68.16% decline from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was $15.53M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$99.34M 10-Q · filed 2026-08-06 | -$155.50M 10-Q · filed 2026-08-06 | -$120.38M derived: sum of 3 quarters · filed 2026-08-06 | -$105.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$56.16M 10-Q · filed 2026-05-07 | -$21.04M derived: sum of 2 quarters · filed 2026-05-07 | -$6.51M derived: sum of 3 quarters · filed 2026-05-07 | -$18.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $35.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $49.65M derived: sum of 2 quarters · filed 2026-02-26 | $37.45M derived: sum of 3 quarters · filed 2026-08-06 | $20.02M 10-K · filed 2026-02-26 |
| 2025-09-30 | $14.53M 10-Q · filed 2025-11-06 | $2.32M derived: sum of 2 quarters · filed 2026-08-06 | -$15.10M 10-Q · filed 2025-11-06 | -$13.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$12.20M 10-Q · filed 2026-08-06 | -$33.79M 10-Q · filed 2026-08-06 | -$27.92M derived: sum of 3 quarters · filed 2026-08-06 | -$15.59M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$21.59M 10-Q · filed 2026-05-07 | -$15.72M derived: sum of 2 quarters · filed 2026-05-07 | -$3.38M derived: sum of 3 quarters · filed 2026-05-07 | -$20.43M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $5.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $18.21M derived: sum of 2 quarters · filed 2026-02-26 | $1.16M derived: sum of 3 quarters · filed 2026-02-26 | -$937.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $12.33M 10-Q · filed 2025-11-06 | -$4.71M derived: sum of 2 quarters · filed 2025-11-06 | -$6.81M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$17.04M 10-Q · filed 2025-08-07 | -$19.14M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$2.10M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $4.95M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $15.53M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |